Open AccessHigh‐level expression of ARID 1A predicts a favourable outcome in triple‐negative breast cancer patients receiving paclitaxel‐based chemotherapy
Author(s) -
Lin YuanFeng,
Tseng IngJy,
Kuo ChihJung,
Lin HuiYu,
Chiu IJen,
Chiu HuiWen
Publication year - 2018
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/jcmm.13551
Subject(s) - paclitaxel , triple negative breast cancer , chemotherapy , breast cancer , medicine , oncology , cancer research , cancer
Paclitaxel‐based chemotherapy is a common strategy to treat patients with triple‐negative breast cancer ( TNBC ). As paclitaxel resistance is still a clinical issue in treating TNBC s, identifying molecular markers for predicting pathologic responses to paclitaxel treatment is thus urgently needed. Here, we report that an AT ‐rich interaction domain 1A ( ARID 1A ) transcript is up‐regulated in paclitaxel‐sensitive TNBC cells but down‐regulated in paclitaxel‐resistant cells upon paclitaxel treatment. Moreover, ARID 1A expression was negatively correlated with the IC 50 concentration of paclitaxel in the tested TNBC cell lines. Kaplan‐Meier analyses revealed that ARID 1A down‐regulation was related to a poorer response to paclitaxel‐based chemotherapy in patients with TNBC s as measured by the recurrence‐free survival probability. The pharmaceutical inhibition with p38 MAPK ‐specific inhibitor SCIO ‐469 revealed that p38 MAPK ‐related signalling axis regulates ARID 1A expression and thereby modulates paclitaxel sensitivity in TNBC cells. These findings suggest that ARID 1A could be used as a prognostic factor to estimate the pathological complete response for TNBC patients who decide to receive paclitaxel‐based chemotherapy.